Table 2 Clinical evaluation of small-molecule IGF-IR inhibitors in cancer patients
Drug | Combination | Cancer type | Phase | Participants | Response | Ref. or trial ID |
|---|---|---|---|---|---|---|
Linsitinib (OSI-906) | None | Locally advanced or metastatic adrenocortical carcinoma | 3 | 139 | OS, 323 days (95% CI 256–507) for linsitinib, 356 days (95% CI 249–556) for placebo | [158] NCT00924989 |
Linsitinib | None | Recurrent small cell lung cancer | 2 | 44 | SD, 3.45%; PFS, 1.2 months (95% CI 1.1–1.4); OS, 3.4 months (95% CI 1.8–5.6). The response to linsitinib is inferior to topotecan. | [159] NCT01533181 |
Linsitinib | Everolimus | Refractory metastatic colorectal cancer | 1 | 18 | No objective responses to treatment. PFS, 8 weeks (95% CI 7–9); OS, 30.6 weeks (95% CI 16.7–32.1) | |
Linsitinib | None | Metastatic prostate cancer | 2 | 17 | PSA partial response, 5.88%; PR, 10%; SD,80%; PD, 10%; PFS, 4.7 months (95% CI 3–6.7) | [161] NCT01533246 |
Linsitinib | Erlotinib | Advanced non-small cell lung cancer | 2 | 88 | Combination of linsitinib with erlotinib resulted in an increase in the incidence of renal and hepatic toxicities compared to erlotinib alone. Combination of linsitinib with erlotinib did not improve the PFS and OS compared to erlotinib alone. | NCT01221077 |
Linsitinib | None | Gastrointestinal stromal tumors | 2 | 20 | CR + PR + SD (≥ 9 months), 40%; PFS rate at 9 months, 52%; OS rate at 9 months, 80% | [162] NCT01560260 |
AXL1717 | None | Recurrent or progressive malignant astrocytoma | 1 | 9 | Tumor response rate, 44%; SD for 12 months, 22.2% | [163] NCT00562380 |